Sentinel Node Biopsy in Melanoma Remains a Valuable Clinical Tool. Comment on Dixon et al. Primary Cutaneous Melanoma-Management in 2024. J. Clin. Med. 2024, 13, 1607

Thomas E Pennington; John F Thompson

doi:10.3390/jcm14010215

Sentinel Node Biopsy in Melanoma Remains a Valuable Clinical Tool. Comment on Dixon et al. Primary Cutaneous Melanoma-Management in 2024. J. Clin. Med. 2024, 13, 1607

J Clin Med. 2025 Jan 2;14(1):215. doi: 10.3390/jcm14010215.

Authors

Thomas E Pennington^{1

2

3}, John F Thompson^{1

2

3}

Affiliations

¹ Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2050, Australia.
² Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2050, Australia.
³ Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia.

Abstract

Management of melanoma in 2024 requires at times complex decision making and a multidisciplinary approach. An article by Dixon and collaborators published in this Journal contained broad-reaching recommendations, some of which are in contradiction of accepted National and International Guidelines. This article seeks to highlight these points of contention and outline widely accepted standards of care that are considered best practice.

Keywords: melanoma; multidisciplinary care; sentinel node biopsy.